- Home
- VFL vs COYA Comparison
VFL vs COYA Comparison
Compare VFL & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VFL
- COYA
- Stock Information
- Founded
- VFL 1993
- COYA 2020
- Country
- VFL United States
- COYA United States
- Employees
- VFL N/A
- COYA N/A
- Industry
- VFL Finance/Investors Services
- COYA Biotechnology: Pharmaceutical Preparations
- Sector
- VFL Finance
- COYA Health Care
- Exchange
- VFL Nasdaq
- COYA Nasdaq
- Market Cap
- VFL 116.3M
- COYA 107.0M
- IPO Year
- VFL N/A
- COYA 2022
- Fundamental
- Price
- VFL $10.23
- COYA $6.10
- Analyst Decision
- VFL
- COYA Strong Buy
- Analyst Count
- VFL 0
- COYA 5
- Target Price
- VFL N/A
- COYA $16.20
- AVG Volume (30 Days)
- VFL 38.0K
- COYA 85.7K
- Earning Date
- VFL 01-01-0001
- COYA 11-05-2025
- Dividend Yield
- VFL 4.16%
- COYA N/A
- EPS Growth
- VFL N/A
- COYA N/A
- EPS
- VFL N/A
- COYA N/A
- Revenue
- VFL N/A
- COYA $423,452.00
- Revenue This Year
- VFL N/A
- COYA $40.80
- Revenue Next Year
- VFL N/A
- COYA N/A
- P/E Ratio
- VFL N/A
- COYA N/A
- Revenue Growth
- VFL N/A
- COYA N/A
- 52 Week Low
- VFL $7.93
- COYA $4.65
- 52 Week High
- VFL $10.77
- COYA $10.24
- Technical
- Relative Strength Index (RSI)
- VFL 61.64
- COYA 55.10
- Support Level
- VFL $10.11
- COYA $5.10
- Resistance Level
- VFL $10.34
- COYA $5.93
- Average True Range (ATR)
- VFL 0.09
- COYA 0.32
- MACD
- VFL -0.02
- COYA 0.06
- Stochastic Oscillator
- VFL 38.71
- COYA 91.75
About VFL abrdn National Municipal Income Fund
Delaware Investments Natl Muni Income is a closed-end investment fund. The Fund seeks to provide current income exempt from regular federal income tax consistent with the preservation of capital. The company's product portfolio includes Mutual funds, Exchange-traded funds, Private markets, Delaware Funds by Macquarie Premier Models, Managed accounts, Closed-end funds, and Variable Insurance Products.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.